Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Titel:
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Auteur:
Pusztai, Lajos Yau, Christina Wolf, Denise M. Han, Hyo S. Du, Lili Wallace, Anne M. String-Reasor, Erica Boughey, Judy C. Chien, A. Jo Elias, Anthony D. Beckwith, Heather Nanda, Rita Albain, Kathy S. Clark, Amy S. Kemmer, Kathleen Kalinsky, Kevin Isaacs, Claudine Thomas, Alexandra Shatsky, Rebecca Helsten, Theresa L. Forero-Torres, Andres Liu, Minetta C. Brown-Swigart, Lamorna Petricoin, Emmanuel F. Wulfkuhle, Julia D. Asare, Smita M. Wilson, Amy Singhrao, Ruby Sit, Laura Hirst, Gillian L. Berry, Scott Sanil, Ashish Asare, Adam L. Matthews, Jeffrey B. Perlmutter, Jane Melisko, Michelle Rugo, Hope S. Schwab, Richard B. Symmans, W. Fraser Yee, Doug van’t Veer, Laura J. Hylton, Nola M. DeMichele, Angela M. Berry, Donald A. Esserman, Laura J.